ELECTROCHEMICAL ANALYSIS OF ZINECARD IN  PHARMACEUTICAL AND BIOLOGICAL SAMPLES

Chennupalle Nageswara Reddy; Puthalapattu Reddy Prasad; Neelam Yugandhar Sreedhar

doi:10.14499/indonesianjpharm23iss3pp147-155

ELECTROCHEMICAL ANALYSIS OF ZINECARD IN PHARMACEUTICAL AND BIOLOGICAL SAMPLES

Chennupalle Nageswara Reddy, Puthalapattu Reddy Prasad, Neelam Yugandhar Sreedhar

Abstract

Zinecard is used to prevent a toxic effect to heart caused by certain medicines that are used to treat cancer. Zinecard is also used to treat tissue damage caused by the leakage of certain medicines that are used to treat cancer. Differential pulse polarographic method developed for the quantitative determination of zinecard gives a peak at -0.32 V at DME. From the structural point of view zinecard contains a >C=Omoiety which can be electrochemically reduced at universal buffer (pH 4.0). Millicoulometric experiment is performed successfully in estimating the number of electrons and proton to understand reduction mechanism. The differential pulse polarographic peak was adequately well-resolved, reproducible and linear dependent with the zinecard concentration. For quantification the calibration plot for zinecard concentrations ranging between 1.0×10^-5mol dm^-3 to 1.0×10^-8mol dm^-3 at pH 4.0 was selected. The proposed differential pulse polarographic method was successfully applied to the determination of zinecard in pharmaceutical formulations and urine samples.

Key words: Zinecard, DPP, pharmaceutical formulations and urine samples.

Full Text:

Untitled

References

Bjelogrlic S.K., RadicJ., Radulovic S., Jokanovic and M., Jovic V., 2007, Effects of dexrazo-xane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo. Exp Biol Med. 232(11):1414-24.

Cvetković R.S., and Scott L.J., Dexrazoxane 2005, A review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 65(7):1005-24.

Hasinoff B.B., and Semin Oncol. 1998, Chemistry of dexrazoxane and analogues 25, 3-9.

Hasinoff, B.B., 1994b, Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (1)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J. Pharm. Sci. 83, 64 – 67.

Hasinoff, BB., 1994a, An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (1)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int. J. Pharm. 107:67–76.

Kane Robert C., McGuinn, W., David, Dagher., Ramzi Justice., Robert Pazdur., and Richard 2008. "Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemo-therapy". The Oncologist 13 (4): 445–50.

Lipshultz S.E., Rifai N., Dalton VM., 2004. "The effect of dexrazoxane on myocardial injury in doxorubicintreated children with acute lymphoblastic leukemia". N. Engl. J. Med.351, 145–53.

McEvoy G., 2005. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists.

Wiseman L.R., and Spencer C.M., 1998, Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapyb . Drugs, 56(3), 385-403.

DOI: http://dx.doi.org/10.14499/indonesianjpharm23iss3pp147-155